SymBio Pharmaceuticals Limited [4582.T]
TOKYO, May 18 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) has secured supply agreements with Nippon Steel Chemical & Material Corporation and Nippon Gene Co., Ltd. for its high-sensitivity immunoassay system aimed at detecting picogram-level antigens.
The agreements establish a stable supply chain for commercializing the technology, which can detect viral antigens down to 1 picogram per mL on-site and in real-time. This breakthrough Point of Care Testing (POCT) system enables early diagnosis and treatment across various fields, including cancer and Alzheimer's disease. The company obtained domestic patents for the technology in October 2025 and is pursuing international patent protection through the Patent Cooperation Treaty (PCT).
Commenting on the development, President and CEO Fumiki Yoshida stated, “We are delighted to have established a robust supply framework with our partners. We believe this ultra-sensitive POCT system will revolutionize diagnostics and meet diverse global healthcare needs.” The agreement is expected to contribute to the company’s mission of addressing unmet medical needs and advancing precision medicine. It does not impact the consolidated earnings forecast for the fiscal year ending December 2026.
🟢 Confidence: High AI-translated content.